Natera reports EPS in-line, beats on revs; guides FY19 revs in-line
- Reports Q4 (Dec) loss of $0.51 per share, in-line with the S&P Capital IQ Consensus of ($0.51); revenues rose 28.8% year/year to $67 mln vs the $63.9 mln S&P Capital IQ Consensus.
- Co issues in-line guidance for FY19, sees FY19 revs of $275-302 mln vs. $287.47 mln S&P Capital IQ Consensus.
- 2018 was a very successful year for Natera," said Steve Chapman, Natera's Chief Executive Officer. "We grew revenues substantially over 2017, doubled our volume growth rate year over year, and delivered compelling data in both oncology and in kidney transplant rejection. We see 2019 as a key inflection point for Natera across reproductive health, oncology, and transplant."
